Prospective Validation of the OHI Index

Last updated: May 8, 2025
Sponsor: Meir Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hematologic Neoplasms

Blood Cancer

Histiocytoma

Treatment

N/A

Clinical Study ID

NCT05882175
0321-19-MMC
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) > 3,900 U/mL and ferritin >1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with hematologic malignancies

  • At least 18 years old

Exclusion

Exclusion Criteria:

  • Prior recent treatment (chemotherapy/ other cytoreductive therapies in the lastmonth)

Study Design

Total Participants: 300
Study Start date:
March 03, 2021
Estimated Completion Date:
March 03, 2030

Study Description

The investigators will enroll patients with new/transformed hematologic malignancies. The investigators will follow the patients until the end of the study, report their survival at one year and examine their prognosis.

Connect with a study center

  • Meir Medical Center

    Kfar Saba, 4428164
    Israel

    Active - Recruiting

  • Rabin Medical Center

    Petach Tikva, 49100
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.